MYCN

Summary

Gene Symbol: MYCN
Description: v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
Alias: MODED, N-myc, NMYC, ODED, bHLHe37, N-myc proto-oncogene protein, class E basic helix-loop-helix protein 37, neuroblastoma MYC oncogene, neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene, oncogene NMYC, pp65/67, v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived
Species: human

Top Publications

  1. ncbi Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
    Frank Westermann
    Department of Tumor Genetics, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany
    Genome Biol 9:R150. 2008
  2. ncbi The MYCN oncogene is a direct target of miR-34a
    J S Wei
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD 20892, USA
    Oncogene 27:5204-13. 2008
  3. ncbi N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor
    Rebecca Cotterman
    Department of Cell Biology, University of California Davis School of Medicine, Davis, California 95616, USA
    Cancer Res 68:9654-62. 2008
  4. ncbi Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation
    Derek M Murphy
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e8154. 2009
  5. ncbi p53 is a direct transcriptional target of MYCN in neuroblastoma
    Lindi Chen
    Northern Institute for Cancer Research, Newcastle University, Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne NE2 4H, United Kingdom
    Cancer Res 70:1377-88. 2010
  6. ncbi Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas
    Olesya Chayka
    Molecular Haematology and Cancer Biology Unit, UCL Institute of Child Health, 30 Guilford St, London WC1N 1EH, UK
    J Natl Cancer Inst 101:663-77. 2009
  7. ncbi N-MYC regulates focal adhesion kinase expression in human neuroblastoma
    Elizabeth A Beierle
    Department of Surgery, University of Florida, Gainesville, Florida 32610, USA
    J Biol Chem 282:12503-16. 2007
  8. ncbi N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b
    Rebecca Cotterman
    Department of Cell Biology and Human Anatomy, and Stem Cell Program, University of California Davis School of Medicine, Shriners Hospital for Children Northern California, Sacramento, California, USA
    PLoS ONE 4:e5799. 2009
  9. ncbi Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma
    H Ochiai
    Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan
    Oncogene 29:2681-90. 2010
  10. ncbi Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival
    Isabella Bray
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e7850. 2009

Research Grants

  1. N-myc Targeted Therapeutics for Childhood Neuroblastoma
    CATHERINE BURKHART; Fiscal Year: 2007
  2. CLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMA
    Robert Seeger; Fiscal Year: 2001
  3. Apoptotic Pathway Defects in Neuroblastoma
    Jill Lahti; Fiscal Year: 2009
  4. Apoptotic Pathway Defects in Neuroblastoma
    Jill Lahti; Fiscal Year: 2006
  5. Apoptotic Pathway Defects in Neuroblastoma
    VINCENT KIDD; Fiscal Year: 2003
  6. Localization and Function of iNKT Cells in Neuroblastoma
    LEONID METELITSA; Fiscal Year: 2009
  7. Localization and Function of iNKT Cells in Neuroblastoma
    LEONID METELITSA; Fiscal Year: 2007
  8. POST TRANSCRIPTIONAL CONTROL OF THE HUMAN N MYC GENE
    William Carroll; Fiscal Year: 2002
  9. FLUORESCENT TISH PROBES FOR CANCER REVELANT SEQUENCES
    JACQUES FRESCO; Fiscal Year: 2004
  10. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2009

Detail Information

Publications184 found, 100 shown here

  1. ncbi Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
    Frank Westermann
    Department of Tumor Genetics, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany
    Genome Biol 9:R150. 2008
    Amplified MYCN oncogene resulting in deregulated MYCN transcriptional activity is observed in 20% of neuroblastomas and identifies a highly aggressive subtype...
  2. ncbi The MYCN oncogene is a direct target of miR-34a
    J S Wei
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD 20892, USA
    Oncogene 27:5204-13. 2008
    Loss of 1p36 heterozygosity commonly occurs with MYCN amplification in neuroblastoma tumors, and both are associated with an aggressive phenotype...
  3. ncbi N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor
    Rebecca Cotterman
    Department of Cell Biology, University of California Davis School of Medicine, Davis, California 95616, USA
    Cancer Res 68:9654-62. 2008
    ..These findings support a new dual model for Myc chromatin function with important implications for the role of Myc in cancer and stem cell biology, including that of induced pluripotent stem cells...
  4. ncbi Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation
    Derek M Murphy
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e8154. 2009
    ..The single most important prognostic indicator of poor clinical outcome in this disease is genomic amplification of MYCN, a member of a family of oncogenic transcription factors.
  5. ncbi p53 is a direct transcriptional target of MYCN in neuroblastoma
    Lindi Chen
    Northern Institute for Cancer Research, Newcastle University, Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne NE2 4H, United Kingdom
    Cancer Res 70:1377-88. 2010
    b>MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis...
  6. ncbi Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas
    Olesya Chayka
    Molecular Haematology and Cancer Biology Unit, UCL Institute of Child Health, 30 Guilford St, London WC1N 1EH, UK
    J Natl Cancer Inst 101:663-77. 2009
    ..We investigated the role of clusterin in tumor development in mouse models of neuroblastoma...
  7. ncbi N-MYC regulates focal adhesion kinase expression in human neuroblastoma
    Elizabeth A Beierle
    Department of Surgery, University of Florida, Gainesville, Florida 32610, USA
    J Biol Chem 282:12503-16. 2007
    ..The results indicate that N-MYC regulation of FAK expression can control cellular functions in isogenic N-MYC(-/+) (Tet(+/-)) neuroblastoma cell lines...
  8. ncbi N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b
    Rebecca Cotterman
    Department of Cell Biology and Human Anatomy, and Stem Cell Program, University of California Davis School of Medicine, Shriners Hospital for Children Northern California, Sacramento, California, USA
    PLoS ONE 4:e5799. 2009
    ..They also suggest mechanisms by which Myc proteins more generally contribute to maintenance of pluripotency and self-renewal of ESC as well as to iPSC formation...
  9. ncbi Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma
    H Ochiai
    Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan
    Oncogene 29:2681-90. 2010
    ..In this paper, we clarified the direct binding of MYCN to Bmi1 promoter and upregulation of Bmi1 transcription by MYCN...
  10. ncbi Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival
    Isabella Bray
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e7850. 2009
    ..Thirty-seven miRNAs were significantly over- or under-expressed in MYCN amplified tumors relative to MYCN single copy tumors, indicating a potential role for the MYCN transcription factor ..
  11. ncbi MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors
    P Mestdagh
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Oncogene 29:1394-404. 2010
    ..Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN ..
  12. ncbi E2F proteins regulate MYCN expression in neuroblastomas
    Verena Strieder
    Institute of Molecular Biology and Tumor Research IMT, Emil Mannkopff Strasse 2, 35033 Marburg, Germany
    J Biol Chem 278:2983-9. 2003
    Amplification of the MYCN gene, resulting in overexpression of MYCN, distinguishes a subset of neuroblastomas with poor prognosis. The transcription factors driving MYCN expression in neuroblastomas are unknown...
  13. ncbi Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma
    Miguel Alaminos
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Res 63:4538-46. 2003
    Molecular mechanisms through which MYCN expression contributes to the malignant phenotype of neuroblastoma are unknown...
  14. ncbi The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
    Andrew Slack
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Baylor College of Medicine, 1102 Bates Street, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:731-6. 2005
    The MYCN oncogene is the major negative prognostic marker in neuroblastoma with important roles in both the pathogenesis and clinical behavior of this aggressive malignancy...
  15. ncbi Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes
    Linda J Valentijn
    Department of Human Genetics M1 134, Academic Medical Center, University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
    Cancer Res 65:3136-45. 2005
    ..Three regions of chromosomal gain and loss thus affect genes functioning in one pathway in neuroblastoma. They converge to bring the pathway out of balance and prevent Cdc42 mediated differentiation...
  16. ncbi Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation
    Arjen Koppen
    Department of Human Genetics, Academic Medical Center, University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
    Cancer Lett 256:218-28. 2007
    ..Twenty percent of neuroblastomas show amplification of the MYCN oncogene, which correlates with poor prognosis...
  17. ncbi Linking of N-Myc to death receptor machinery in neuroblastoma cells
    Hongjuan Cui
    Department of Biochemistry and Cancer Biology, Medical College of Ohio, Toledo, Ohio 43614, USA
    J Biol Chem 280:9474-81. 2005
    The oncogene MYCN is amplified in aggressive neuroblastomas in which caspase-8, an essential component of death receptor pathways, is frequently inactivated, suggesting a critical role of death receptor-mediated apoptosis in suppression ..
  18. ncbi Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma
    Anu Gupta
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer Res 66:8100-8. 2006
    Neuroblastoma is a heterogeneous disease in which 22% of tumors show MycN oncogene amplification and are associated with poor clinical outcome...
  19. ncbi Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay
    Katleen De Preter
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Mod Pathol 15:159-66. 2002
    Amplification of the proto-oncogene MYCN is a strong adverse prognostic factor in neuroblastoma patients in all tumor stages...
  20. ncbi Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma
    Jason M Shohet
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 62:1123-8. 2002
    The MYCN oncogene is amplified in approximately 25% of neuroblastoma tumors and is the most significant negative prognostic factor. The direct transcriptional targets of MYCN in MYCN-amplified tumors have not been defined...
  21. ncbi Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization
    Cornelia Stock
    Children s Cancer Research Institute, St Anna Kinderkrebsforschung, Kinderspitalgasse 6, A 1090 Vienna, Austria
    Am J Pathol 172:203-14. 2008
    b>MYCN amplification is associated with poor prognosis in neuroblastoma disease...
  22. ncbi N-myc coordinates retinal growth with eye size during mouse development
    Rodrigo A P Martins
    Department of Developmental Neurobiology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Genes Dev 22:179-93. 2008
    ..We propose that N-myc lies upstream of the cell cycle machinery in the developing mouse retina and thus coordinates the growth of both the retina and eye through extrinsic cues...
  23. ncbi N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma
    Elissavet Hatzi
    Laboratory of Biological Chemistry, Medical School, University of Ioannina, Greece
    Eur J Biochem 269:3732-41. 2002
    ..Our data shed light on the mechanisms by which N-myc oncogene amplification enhances the malignant phenotype in neuroblastoma...
  24. ncbi MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells
    Jung Hee Kang
    Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA
    Biochem Biophys Res Commun 351:192-7. 2006
    b>MYCN amplification strongly correlates with unfavorable outcomes in patients with neuroblastoma. The aim of this study was to investigate the role of MYCN in neuroblastoma cell differentiation and apoptosis...
  25. ncbi Genotype-phenotype correlations in MYCN-related Feingold syndrome
    Carlo L M Marcelis
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Hum Mutat 29:1125-32. 2008
    ..FS is caused by germline mutations in or deletions of the MYCN gene...
  26. ncbi Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study
    Lisa A Moreau
    The National Center for Pediatric Cancer Genetics, Children s Oncology Group, University of Florida, Gainesville, FL, USA
    Clin Cancer Res 12:5693-7. 2006
    b>MYCN amplification in neuroblastoma tumor cells is manifested primarily as double minutes (dmins), whereas in cell lines it often appears in the form of homogeneously staining regions (HSR), suggesting that HSRs are associated with a more ..
  27. ncbi Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc
    M Schwab
    Nature 308:288-91. 1984
    ....
  28. ncbi Sequence of a germ-line N-myc gene and amplification as a mechanism of activation
    J M Ibson
    Ludwig Institute for Cancer Research, Cambridge, UK
    Oncogene 2:399-402. 1988
    ....
  29. ncbi Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
    G M Brodeur
    Science 224:1121-4. 1984
    ..Furthermore, N-myc amplification is highly correlated with advanced stages of disease (P less than 0.001) and with the ability to grow in vitro as an established cell line, both of which are associated with a poor prognosis...
  30. ncbi Nucleotide sequence of the human N-myc gene
    L W Stanton
    Proc Natl Acad Sci U S A 83:1772-6. 1986
    ..The resemblance between the proteins encoded by N-myc and c-myc sustains previous suspicions that the genes encode related functions...
  31. ncbi Alternative processing of RNA transcribed from NMYC
    L W Stanton
    Department of Microbiology and Immunology, University of California Medical Center, San Francisco 94143
    Mol Cell Biol 7:4266-72. 1987
    b>NMYC is a gene whose amplification and overexpression have been implicated in the generation of certain human malignancies. Little is known of how the expression of NMYC is normally controlled...
  32. ncbi N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts
    G W Krystal
    Massey Cancer Center, Division of Hematology Oncology, Medical College of Virginia, Richmond
    Mol Cell Biol 10:4180-91. 1990
    ....
  33. ncbi Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group
    Jennifer Schneiderman
    Children s Memorial Hospital, Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    J Clin Oncol 26:913-8. 2008
    b>MYCN amplification is rarely detected in patients with favorable-stage neuroblastoma (NB)...
  34. ncbi Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc
    B C Armstrong
    Department of Medicine, Medical College of Virginia, Richmond, Virginia
    Cell Growth Differ 3:385-90. 1992
    ..This coregulation suggests that their protein products may be functionally interrelated during normal development and oncogenesis...
  35. ncbi The homeobox gene MEIS1 is amplified in IMR-32 and highly expressed in other neuroblastoma cell lines
    T A Jones
    Human Cytogenetics Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, London, UK
    Eur J Cancer 36:2368-74. 2000
    ..High expression of MEIS1 without amplification was also found in other neuroblastoma cell lines, with and without MYCN amplification, and in medulloblastoma and crythroleukaemia cell lines...
  36. ncbi N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification
    M Badiali
    Department of Pediatrics, University of Bologna, Italy
    Tumori 77:118-21. 1991
    ..Medulloblastomas with c-myc activation may represent a subgroup of tumors with a more aggressive behavior...
  37. ncbi Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group
    C P Taylor
    Human Cytogenetics Laboratory, Imperial Cancer Research Fund, Lincoln s Inn Fields, London, UK
    Br J Cancer 83:40-9. 2000
    ..powerful biological parameters associated with prognosis in this malignancy are chromosomal changes, especially MYCN amplification, deletion of chromosome 1p and aneuploidy...
  38. ncbi Rapid detection of prognostic genetic factors in neuroblastoma using fluorescence in situ hybridisation on tumour imprints and bone marrow smears. United Kingdom Children's Cancer Study Group
    C P Taylor
    Human Cytogenetics Laboratory, Imperial Cancer Research Fund, London, UK
    Br J Cancer 69:445-51. 1994
    ....
  39. ncbi Mutations in PIK3CA are infrequent in neuroblastoma
    Vincent Dam
    Division of Oncology, The Children s Hospital of Philadelphia Philadelphia, PA, USA
    BMC Cancer 6:177. 2006
    Neuroblastoma is a frequently lethal pediatric cancer in which MYCN genomic amplification is highly correlated with aggressive disease...
  40. ncbi Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience
    Adela Canete
    Unidad de Oncología Pediátrica, Hospital Infantil La Fe, Avda de Campanar 21, 46009 Valencia, Spain
    J Clin Oncol 27:1014-9. 2009
    To report the results of a prospective, nonrandomized European study on infants with neuroblastoma and MYCN gene amplification.
  41. ncbi [Detection of n-myc gene amplification in neuroblastoma using polymerase chain reaction based methods]
    Zsombor Melegh
    Molekuláris Pathologiai Osztály, Országos Onkológiai Intézet, Budapest, H1122, Hungary
    Magy Onkol 46:43-8. 2002
    ..We used biotinylated ATP labelling and the same primer pair as for the LightCycler analysis.In both cases differentiated cell forms did not show n-myc gene amplification, while considerable amplification was detected in the neuroblasts...
  42. ncbi Microgravity assay of neuroblastoma: in vitro aggregation kinetics and organoid morphology correlate with MYCN expression
    Robert A Redden
    Center for Fetal Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    In Vitro Cell Dev Biol Anim 47:312-7. 2011
    ..Specifically, we examined the effect of amplification of the oncogene MYCN, a genetic factor that is strongly associated with poor clinical outcome...
  43. ncbi Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24
    F Abel
    Department of Clinical Genetics Sahlgrenska University East, Gothenburg, Sweden
    Br J Cancer 81:1402-9. 1999
    Deletion of chromosome arm 1p and amplification of the MYCN oncogene are well-recognized genetic alterations in neuroblastoma cells. Recently, another alteration has been reported; gain of the distal part of chromosome arm 17q...
  44. ncbi N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells
    Daniel Noujaim
    Department of Neurology, University of Michigan, Ann Arbor 48109, USA
    Oncogene 21:4549-57. 2002
    ..These data imply that N-Myc and Bcl-2 cooperate to increase the expression, secretion, and activation of MMP-2, which likely leads to a more tumorigenic phenotype due to increased MMP-2 mediated invasion...
  45. ncbi MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2
    Niamh H Foley
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Mol Cancer 9:83. 2010
    ..The single most important genetic indicator of poor clinical outcome is amplification of the MYCN transcription factor...
  46. ncbi Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma
    S J Meltzer
    Department of Medicine, University of Maryland, Baltimore 21201, USA
    Br J Cancer 74:1855-61. 1996
    ..These data suggest that allelic imbalance of chromosome 5 is involved in at least a subset of neuroblastomas and influences survival in patients with neuroblastoma...
  47. ncbi Surgery in pediatric solid tumors with special reference to advanced neuroblastoma
    Yoshiaki Tsuchida
    Department of Surgery, Gunma Children s Medical Center, Seta gun, Japan
    Acta Paediatr Taiwan 43:67-71. 2002
    The role of surgery in Wilms' tumor and hepatoblastoma is well established, but that in advanced neuroblastoma is controversial. We analyzed factors contributing to the long-term survival of patients with MYCN-amplified neuroblastoma.
  48. ncbi Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
    Rochelle Bagatell
    University of Arizona Health Sciences Center, Tucson, AZ, USA
    J Clin Oncol 27:365-70. 2009
    ..To evaluate the outcome of children with low-stage MYCN-amplified neuroblastoma and develop a rational treatment strategy, data from the International Neuroblastoma Risk ..
  49. ncbi Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma
    Ruediger Spitz
    University of Cologne, Children s Hospital, Pediatric Oncology, 50924 Köln, Germany
    Clin Cancer Res 9:4835-40. 2003
    ..long arm of chromosome 17 was shown to be a frequent and prognostically relevant factor in neuroblastoma, in addition to MYCN amplification (MNA) or 1p deletion. We asked whether this observation could be confirmed in a German cohort.
  50. ncbi Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma
    Elizabeth A Beierle
    Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, USA
    Cell Cycle 9:1005-15. 2010
    ..FAK is overexpressed in a number of human tumors including neuroblastoma. Previously, we have shown that the MYCN oncogene, the primary adverse prognostic indicator in neuroblastoma, regulates the expression of FAK in ..
  51. ncbi The neuroblastoma amplified gene, NAG: genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma
    D K Scott
    Cancer Research Unit, Northern Institute of Cancer Research, University of Newcastle Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Gene 307:1-11. 2003
    Amplification of the MYCN oncogene in neuroblastoma is associated with poor prognosis. The amplified unit of DNA can be up to 1 Mb in size and so could contain additional genes which affect tumour phenotype...
  52. ncbi Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study
    Mary Lou Schmidt
    Department of Pediatrics, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA
    J Clin Oncol 23:6474-80. 2005
    The long-term survival of children between age 12 and 24 months with stage 4 neuroblastoma and nonamplified MYCN (MYCN-NA) has not been defined previously.
  53. ncbi Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma
    Shigeki Yagyu
    Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kamigyo ku, Kyoto, Japan
    Clin Cancer Res 14:7011-9. 2008
    b>MYCN amplification (MNA) in neuroblastoma is a strong indicator of poor prognosis...
  54. ncbi Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1
    E Hiyama
    Department of General Medicine, Hiroshima University School of Medicine, Japan
    Med Pediatr Oncol 36:67-74. 2001
    ..It is well known that almost all cases with MYCN amplification have a poor prognosis...
  55. ncbi Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma
    Paul L Regan
    Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Int J Oncol 38:105-12. 2011
    Neuroblastoma is a childhood cancer that exhibits either a favorable or an unfavorable phenotype. MYCN and MYC are oncoproteins that play crucial roles in determining the malignancy of unfavorable neuroblastoma...
  56. ncbi Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Cancer Res 66:10016-23. 2006
    Inactivation of caspase-8 because of aberrant gene methylation has been associated with amplification of the MYCN oncogene and aggressive disease in neuroblastoma, suggesting that caspase-8 may function as tumor suppressor...
  57. ncbi High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene
    Helena Caren
    Department of Clinical Genetics, Institute of Biomedicine, Goteborg University, Sahlgrenska University Hospital, SE 41345 Goteborg, Sweden
    BMC Genomics 9:353. 2008
    ..We have used array-based copy number analysis using oligonucleotide single nucleotide polymorphisms (SNP) arrays to analyze the chromosomal structure of a large number of neuroblastoma tumors of different clinical and biological subsets...
  58. ncbi Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction
    Louis Chesler
    Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
    Neoplasia 10:1268-74. 2008
    Chemoresistance in neuroblastoma is a significant issue complicating treatment of this common pediatric solid tumor. MYCN-amplified neuroblastomas are infrequently mutated at p53 and are chemosensitive at diagnosis but acquire p53 ..
  59. ncbi Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma
    Nibal Zaghloul
    Department of Pediatrics, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    Int J Oncol 34:401-7. 2009
    ..Amplification of the MYCN proto-oncogene is a significant marker of these poor-prognosis neuroblastoma tumors...
  60. ncbi Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis
    Yongxin Chen
    Children s Cancer Research Institute and Department of Pediatrics, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229, USA
    Cancer Res 67:976-83. 2007
    Neuroblastoma accounts for 15% of pediatric cancer deaths, and although a few protein-coding genes, such as MYCN, are involved with aggressive pathogenicity, the identification of novel biological targets for therapeutic intervention is ..
  61. ncbi Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha
    Guoliang Qing
    Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Cancer Res 70:10351-61. 2010
    In human neuroblastoma, amplification of the MYCN gene predicts poor prognosis and resistance to therapy...
  62. ncbi Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas
    Jaime Torres
    Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Int J Oncol 37:983-91. 2010
    ..The tumor exhibits two different phenotypes: favorable and unfavorable. MYCN amplification is associated with rapid tumor progression and the worst neuroblastoma disease outcome...
  63. ncbi Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse
    E Ferrandis
    Laboratory of Clinical and Molecular Pharmacology, Institut Gustave Roussy, Villejuif, France
    Cancer Res 54:2256-61. 1994
    In metastatic human neuroblastoma, MYCN amplification and MDR1 overexpression are frequently observed. No in vivo model is yet available for the study of the regulation of these two genes during the metastatic process of this disease...
  64. ncbi c- and N-myc regulate neural precursor cell fate, cell cycle, and metabolism to direct cerebellar development
    Alice Wey
    Institute of Pediatric Regenerative Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA
    Cerebellum 9:537-47. 2010
    ..Together these findings indicate that c- and N-Myc direct cerebellar development by maintaining CGNP and NSC populations through inhibiting differentiation as well as directing rapid cell cycling and active cellular metabolism...
  65. ncbi c-myc and N-myc promote active stem cell metabolism and cycling as architects of the developing brain
    Alice Wey
    Institute of Pediatric Regenerative Medicine, Department of Cell Biology and Human Anatomy, University of California Davis School of Medicine, Shriners Hospital for Children Northern California, Sacramento, CA 95817, USA
    Oncotarget 1:120-30. 2010
    ....
  66. ncbi [Study on MYCN gene amplification and CD44 expression in neuroblastoma]
    Hui li Hu
    Department of Pathology, Beijing Children s Hospital, The Capital University of Medical Science, Beijing 100045, China
    Zhonghua Bing Li Xue Za Zhi 33:332-6. 2004
    To assess the relationship between MYCN amplification in neuroblastoma (NB), tumor stage and prognosis; and to evaluate the usefulness of CD44 in predicting prognosis of NB.
  67. ncbi MYCN protein expression as a predictor of neuroblastoma prognosis
    H S Chan
    Division of Hematology Oncology and Immunology, Department of Pediatrics, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, M5G 1X8 Canada
    Clin Cancer Res 3:1699-706. 1997
    About half of nonlocalized neuroblastomas have MYCN gene amplification and usually progress rapidly, but the half without such amplification also do poorly, albeit progressing more slowly...
  68. ncbi Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma
    E Hiyama
    Department of General Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
    Clin Cancer Res 5:601-9. 1999
    Amplification of the MYCN gene and high telomerase activity predict a poor prognosis for the patients with neuroblastoma...
  69. ncbi Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop
    B R Stanton
    Molecular Embryology Section, National Cancer Institute Frederick Cancer Research and Development Center, Maryland 21702 1201
    Genes Dev 6:2235-47. 1992
    ..Examination of c-myc expression in mutant embryos indicates the existence of coordinate regulation of myc genes during mouse embryogenesis...
  70. ncbi IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression
    R Dildrop
    Howard Hughes Medical Institute, New York, NY
    EMBO J 8:1121-8. 1989
    ..Our results also are discussed in the context of differential myc gene activity in normal and transformed cells...
  71. ncbi The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2
    Marc B Godfried
    Department of Human Genetics, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Oncogene 21:2097-101. 2002
    ..These observations suggest a major role for nm23-H1 and nm23-H2 in tumorigenesis of unfavorable neuroblastomas...
  72. ncbi HuD, a neuronal-specific RNA-binding protein, is a putative regulator of N-myc pre-mRNA processing/stability in malignant human neuroblasts
    D L Lazarova
    Department of Biological Sciences, Fordham University, Bronx, New York 10458, USA
    Oncogene 18:2703-10. 1999
    ..In sense and antisense HuD-transfected N cells, there are coordinate changes in HuD and N-myc expression levels. Thus, we propose that HuD plays a role in the nuclear processing/stability of N-myc pre-mRNA in N-type neuroblastoma cells...
  73. ncbi Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
    N Bown
    Department of Human Genetics, University of Newcastle upon Tyne, United Kingdom
    N Engl J Med 340:1954-61. 1999
    ..We investigated these associations and evaluated the prognostic importance of the status of chromosome 17...
  74. ncbi The human myc gene family: structure and activity of L-myc and an L-myc pseudogene
    R A DePinho
    Howard Hughes Medical Institute, New York
    Genes Dev 1:1311-26. 1987
    ..Our analyses clearly prove that L-myc represents a functional member of the myc oncogene family and further delineate structural features that may be important for the common and divergent functions of the members of this gene family...
  75. ncbi Pax-2 and N-myc regulate epithelial cell proliferation and apoptosis in a positive autocrine feedback loop
    Shao Ling Zhang
    University of Montreal, Centre hospitalier de l Université de Montréal CHUM Hôtel Dieu, 3850 Saint Urbain Street, Montreal, Quebec, H2W 1T7, Canada
    Pediatr Nephrol 22:813-24. 2007
    ..Our data demonstrate that Pax-2 gene overexpression prevents hyperglycemia-induced apoptosis, and N-myc appears to provide a positive autocrine feedback on Pax-2 gene expression in embryonic mesenchymal cells...
  76. ncbi Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR
    Ryota Souzaki
    Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Pediatr Surg Int 24:1095-100. 2008
    Recently, determining the MYCN status in neuroblastoma (NB) using the quantitative PCR (Q-PCR) and FISH instead of the Southern blotting (SB) has been recommended...
  77. ncbi Heterogeneity of the MYCN oncogene in neuroblastoma
    Jessica Theissen
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Clin Cancer Res 15:2085-90. 2009
    b>MYCN amplification is an important therapy-stratifying marker in neuroblastoma. Fluorescence in situ hybridization with signal detection on the single-cell level allows a critical judgement of MYCN intratumoral heterogeneity.
  78. ncbi Peripheral neuroblastic tumours in eastern Denmark 1972-2002
    Zarah Glad Zimling
    Department of Pathology, University of Copenhagen, Denmark
    APMIS 115:66-74. 2007
    ..We have evaluated the histological presentation, MYCN gene status, and clinical course of peripheral neuroblastic tumours diagnosed and treated in eastern Denmark from ..
  79. ncbi Molecular therapy of human neuroblastoma cells using Auger electrons of 111In-labeled N-myc antisense oligonucleotides
    Naoyuki Watanabe
    Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan
    J Nucl Med 47:1670-7. 2006
    ..We investigated the therapeutic effect of Auger electrons emitted by 111In-labeled phosphorothioate antisense oligonucleotides on human neuroblastoma cells in which N-myc was overexpressed...
  80. ncbi Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping
    Batia Stark
    Cancer Cytogenetic Laboratory, Schneider Children s Medical Center of Israel, Petah Tiqva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Genes Chromosomes Cancer 34:313-24. 2002
    Molecular studies of advanced-stage neuroblastoma (NBL) have revealed a marked genetic heterogeneity. In addition to MYCN amplification and chromosome 1 short-arm deletions/translocations detected by conventional cytogenetics, application ..
  81. ncbi Functional homology between N-myc and c-myc in murine plasmacytomagenesis: plasmacytoma development in N-myc transgenic mice
    Y Wang
    Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
    Oncogene 7:1241-7. 1992
    ..All plasmacytomas expressed the N-myc transgene, while none of them expressed either c-myc or endogenous N-myc. None of the tumors carried the usual plasmacytoma-associated translocations...
  82. ncbi The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors
    Andrea Pession
    Department of Pediatrics, University of Bologna, S Orsola Hospital, Bologna, Italy
    Curr Cancer Drug Targets 5:273-83. 2005
    b>MYCN belongs to the MYC family of proto-oncogenes, which encode for transcription factors of the basic-helix-loop-helix-zipper (bHLHZ) class and is fundamental in the development of the peripheral and central nervous systems (PNS and CNS)...
  83. ncbi Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells
    Yuichi Murakami
    Department of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812 8582, Japan
    Biochem Biophys Res Commun 396:376-81. 2010
    ..Phosphorylation of NDRG1/Cap43 at both serine330 and threonine346 is required for its suppressive action on the NF-kappaB signaling pathway and CXC chemokine expression in pancreatic cancer cells...
  84. ncbi N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease
    I Ferrer
    Unitat de Neuropatologia, Servei d Anatomia Patològica, Hospital Princeps d Espanya, i Departament de Biologia Cel lular i Anatomia Patològica, Facultat de Medicina, Universitat de Barcelona, Hospitalet de Llobregat, Llobregat, Spain
    Brain Res Mol Brain Res 77:270-6. 2000
    ..Increased N-myc and c-myc expression in reactive astrocytes probably plays a role in reactive astrocytosis in human neurodegenerative disorders...
  85. ncbi Radiosensitivity of small-cell lung cancer xenografts compared with activity of c-myc, N-myc, L-myc, c-raf-1 and K-ras proto-oncogenes
    K Rygaard
    Institute of Pathological Anatomy, University of Copenhagen, Denmark
    Int J Cancer 49:279-84. 1991
    ..No long-term difference in expression of c-raf-1 or c-myc mRNA was detected between control tumours and tumours irradiated with 5 or 10 Gy...
  86. ncbi Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis
    Roberto Tonelli
    Unità di Terapia Cellulare, Dipartimento di Scienze Pediatriche Mediche e Chirurgiche, Policlinico Sant Orsola Malpighi, Via Massarenti 11, 40138 Bologna, Italy
    Mol Cancer Ther 4:779-86. 2005
    We developed an anti-gene peptide nucleic acid (PNA) for selective inhibition of MYCN transcription in neuroblastoma cells, targeted against a unique sequence in the antisense DNA strand of exon 2 of MYCN and linked at its NH(2) terminus ..
  87. ncbi Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation
    Hidehiro Takei
    Department of Pathology, The Methodist Hospital, Texas Children s Cancer Center and Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurosurg Pediatr 3:61-5. 2009
    ..The frequency of low-level copy gain of myc oncogenes and its relationship to prognosis of MB has not been explored...
  88. ncbi Cooperative action of multiple cis-acting elements is required for N-myc expression in branchial arches: specific contribution of GATA3
    Eric Potvin
    Centre de recherche en cancérologie de l Université Laval, 9 rue McMahon, Quebec, QC, Canada
    Mol Cell Biol 30:5348-63. 2010
    ..Together, these data demonstrate that correct N-myc developmental expression is achieved via cooperation of multiple positive and negative regulatory elements...
  89. ncbi TP53, ?-Catenin and c-myc/N-myc status in embryonal tumours with ependymoblastic rosettes
    M Gessi
    Institute of Neuropathology, University of Bonn Medical Center, Bonn, Germany
    Neuropathol Appl Neurobiol 37:406-13. 2011
    ..42, common in both ependymoblastoma and embryonal tumour with abundant neuropil and true rosettes, suggests that they represent a histological spectrum of a single biological entity...
  90. ncbi N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer
    Veerle Melotte
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands
    J Natl Cancer Inst 101:916-27. 2009
    ..Here we examined the role of N-Myc downstream-regulated gene 4 (NDRG4) as a novel tumor suppressor and biomarker in colorectal cancer...
  91. ncbi TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance
    Hiroyuki Shimada
    Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California 90027, USA
    Cancer 101:1873-81. 2004
    ..This study was conducted to investigate the prognostic significance and biologic relevance of trkA expression levels in peripheral neuroblastic tumors (pNTs) (i.e., neuroblastoma, ganglioneuroblastoma, and ganglioneuroma)...
  92. ncbi MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells
    Andrew D Slack
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 67:2448-55. 2007
    ..In neuroblastoma cell lines, MYCN (N-Myc) expression induces centrosome amplification in response to ionizing radiation...
  93. ncbi N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization
    G Mugrauer
    Friedrich Miescher Laboratorium der Max Planck Gesellschaft, Tubingen, Federal Republic of Germany
    J Cell Biol 107:1325-35. 1988
    ..The results raise the possibility that N-myc may participate in the control of these early differentiation events...
  94. ncbi Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy
    Sachiyo Suita
    Department of Pediatric Surgery, Kyushu University, Fukuoka 812 8582, Japan
    J Pediatr Surg 42:489-93. 2007
    This study aims to clarify the implications of MYCN amplification in patients with high-risk neuroblastomas treated with 2 different regimens of induction chemotherapy established by the Japan Study Group for Advanced Neuroblastoma.
  95. ncbi The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification
    Dirk Geerts
    Department of Human Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Int J Cancer 126:2012-24. 2010
    ..Since ODC is a known target gene of MYCN, the correlation between ODC and MYCN was of special interest...
  96. ncbi Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo
    Harun M Said
    Department of Radiation Oncology, University of Wurzburg, D 97080 Wurzburg, Germany
    Oncol Rep 21:237-46. 2009
    ....
  97. ncbi Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan
    S Suita
    Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Eur J Pediatr Surg 17:23-8. 2007
    ....
  98. ncbi Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors
    James R Jacob
    Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
    Hepatology 39:1008-16. 2004
    ....
  99. ncbi Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3
    Kelli K Kanemaru
    Natural Products and Cancer Biology Program, Cancer Research Center of Hawaii, Honolulu, Hawaii, USA
    Pediatr Blood Cancer 50:806-11. 2008
    ..An important event in differentiation is the transcriptional downregulation of the MYCN oncogene, which is frequently activated in aggressive tumors...
  100. ncbi Regulation of MYCN expression in human neuroblastoma cells
    Joannes F M Jacobs
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Donders Institute for Brain, Cognition and Behaviour, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    BMC Cancer 9:239. 2009
    Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB...
  101. ncbi Familial syndromic esophageal atresia maps to 2p23-p24
    J Celli
    Human Genetics, University Hospital Nijmegen, Geert Grooteplein 10, 6500 HB Nijmegen, The Netherlands
    Am J Hum Genet 66:436-44. 2000
    ..Little is known of the genetic factors that underlie EA. Oculodigitoesophageoduodenal (ODED) syndrome (also known as "Feingold syndrome") is a rare autosomal dominant disorder with digital ..

Research Grants63

  1. N-myc Targeted Therapeutics for Childhood Neuroblastoma
    CATHERINE BURKHART; Fiscal Year: 2007
    ....
  2. CLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMA
    Robert Seeger; Fiscal Year: 2001
    ..The specific aims are as follows: (1) determine if tumor phenotype defined by MYCN gene amplification and expression, TrkA expression, telomerase RNA expression, and growth in vitro correlates with ..
  3. Apoptotic Pathway Defects in Neuroblastoma
    Jill Lahti; Fiscal Year: 2009
    Late stage neuroblastoma tumors, particularly those with amplified MYCN genes, have a poor prognosis, primarily due to their ability to survive treatment with multiple chemotherapeutic agents/irradiation...
  4. Apoptotic Pathway Defects in Neuroblastoma
    Jill Lahti; Fiscal Year: 2006
    Late stage neuroblastoma tumors, particularly those with amplified MYCN genes, have a poor prognosis, primarily due to their ability to survive treatment with multiple chemotherapeutic agents/irradiation...
  5. Apoptotic Pathway Defects in Neuroblastoma
    VINCENT KIDD; Fiscal Year: 2003
    Late stage neuroblastoma tumors, particularly those with amplified MYCN genes, have a poor prognosis, primarily due to their ability to survive treatment with multiple chemotherapeutic agents/irradiation...
  6. Localization and Function of iNKT Cells in Neuroblastoma
    LEONID METELITSA; Fiscal Year: 2009
    ....
  7. Localization and Function of iNKT Cells in Neuroblastoma
    LEONID METELITSA; Fiscal Year: 2007
    ....
  8. POST TRANSCRIPTIONAL CONTROL OF THE HUMAN N MYC GENE
    William Carroll; Fiscal Year: 2002
    ....
  9. FLUORESCENT TISH PROBES FOR CANCER REVELANT SEQUENCES
    JACQUES FRESCO; Fiscal Year: 2004
    ....
  10. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2009
    ..One of the most striking abnormalities found in NB tumors is the amplification of the MYCN oncogene, which strongly correlates with more aggressive tumors and poor prognosis of late stage disease...
  11. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2009
    ..One of the most striking abnormalities found in NB tumors is the amplification of the MYCN oncogene, which strongly correlates with more aggressive tumors and poor prognosis of late stage disease...
  12. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2007
    ..high-risk (late stage) NB patients indicates the need for novel therapeutic approaches, including drugs that block MYCN expression...
  13. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William Weiss; Fiscal Year: 2009
    ..Amplification of the transcription factor MYCN occurs frequently in this tumor, and correlates with advanced disease...
  14. Neuroblastoma Tumor Suppressor Genes in Zebrafish
    A Look; Fiscal Year: 2007
    ..important in NB pathogenesis and normal PSNS development; and (ii) transgenic zebrafish overexpressing the human MYCN oncogene in the developing PSNS can be used to determine the role of MYCN amplification in aberrant sympathetic ..
  15. Discovery of Chromosome Arm 11q Tumor Suppressor Genes in Neuroblastoma
    Edward Attiyeh; Fiscal Year: 2007
    ..Most invasive neuroblastomas are defined either by MYCN amplification (40%) or 11q loss of heterozygosity (30%), but rarely do these occur in the same tumor...
  16. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William Weiss; Fiscal Year: 2009
    ..Amplification of the transcription factor MYCN occurs frequently in this tumor, and correlates with advanced disease...
  17. Genetic Susceptibility Factors in the Etiology of Neuroblastoma
    Andrew Olshan; Fiscal Year: 2010
    ..evaluate genetic effects within NB subgroups defined by age at diagnosis and a classification schema based on age, MYCN oncogene status, histology, and DNA ploidy...
  18. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William A Weiss; Fiscal Year: 2010
    ..Amplification of the transcription factor MYCN occurs frequently in this tumor, and correlates with advanced disease...
  19. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William A Weiss; Fiscal Year: 2011
    ..Amplification of the transcription factor MYCN occurs frequently in this tumor, and correlates with advanced disease...